PET Imaging of Brain Tumors
The incidence of primary brain tumors is ~ 11:100,000 of the population. In the year 2006, ~ 18,820 new cases of brain and other nervous system tumors were diagnosed in the United States [1] and these tumors were the cause of death in ~ 12,820 patients. Despite advances in diagnosis and therapy, the...
Gespeichert in:
Veröffentlicht in: | Cancer Treatment and Research 2008, Vol.143, p.67-92 |
---|---|
1. Verfasser: | |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 92 |
---|---|
container_issue | |
container_start_page | 67 |
container_title | Cancer Treatment and Research |
container_volume | 143 |
creator | Fischman, Alan J. |
description | The incidence of primary brain tumors is ~ 11:100,000 of the population. In the year 2006, ~ 18,820 new cases of brain and other nervous system tumors were diagnosed in the United States [1] and these tumors were the cause of death in ~ 12,820 patients. Despite advances in diagnosis and therapy, the prognosis for patients with primary brain tumors remains very poor; age-adjusted five-year survival is 30.8 percent. Primary brain tumor is the most prevalent solid tumor in children, and patients 19 years old or younger have a five-year survival of 65 percent. Patients aged 44 or younger have a five-year survival of 58.7 percent. In the elderly, prognosis is extremely poor with a five-year survival of less than 6.5 percent in patients aged 65 and older [1].
The epidemiology of primary brain tumors is extremely complex and includes lesions with both benign and malignant histologies. Between 1985 and 1992, over 60,000 patients diagnosed with primary brain tumors were reported to the National Cancer Data Base (NCDB) [2], and in this group the most frequent tumors were glioblastoma multiforme (GBM) and astrocytoma. The World Health Organization (WHO) has established a four-level classification system (Grade I to IV) with Grade I being most benign, and Grade IV most malignant. The most malignant tumors - astrocytomas and GBM (Grade III to IV) - had overall 30 percent and two percent five-year survival in the NCDB series [2]. |
doi_str_mv | 10.1007/978-0-387-75587-8_3 |
format | Article |
fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_miscellaneous_21242928</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>21242928</sourcerecordid><originalsourceid>FETCH-LOGICAL-c2473-58c3fa084fc22435ff55246332f5d65f089757d0a6023e1670a4e22f66fa95393</originalsourceid><addsrcrecordid>eNo1kE1PwzAMhoMAwTb2CyahnrgFHOf7CNOASZPgMM5R1iVTYW1HQw_8e8I-Lrb8-pElP4RMGNwzAP1gtaFAudFUS5mrcfyMjHMKOdtH5pwMT4NiF2QAFjXlIPCaDFP6BJAaNb8i1yzvLTIxIJP32bKY135TNZuijcVT56umWPZ126Ubchn9NoXxsY_Ix_NsOX2li7eX-fRxQUsUmlNpSh49GBFLRMFljFKiUJxjlGslIxirpV6DV4A8MKXBi4AYlYreSm75iNwd7u669rsP6cfVVSrDduub0PbJIUOBFk0Gb49gv6rD2u26qvbdrzu9kwF2AFJeNZvQuVXbfiXHwP07dNmWA5cVub0wlx3yP4cHWvo</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>21242928</pqid></control><display><type>article</type><title>PET Imaging of Brain Tumors</title><source>MEDLINE</source><source>Springer Books</source><creator>Fischman, Alan J.</creator><contributor>Blake, Michael A. ; Kalra, Mannudeep K.</contributor><creatorcontrib>Fischman, Alan J. ; Blake, Michael A. ; Kalra, Mannudeep K.</creatorcontrib><description>The incidence of primary brain tumors is ~ 11:100,000 of the population. In the year 2006, ~ 18,820 new cases of brain and other nervous system tumors were diagnosed in the United States [1] and these tumors were the cause of death in ~ 12,820 patients. Despite advances in diagnosis and therapy, the prognosis for patients with primary brain tumors remains very poor; age-adjusted five-year survival is 30.8 percent. Primary brain tumor is the most prevalent solid tumor in children, and patients 19 years old or younger have a five-year survival of 65 percent. Patients aged 44 or younger have a five-year survival of 58.7 percent. In the elderly, prognosis is extremely poor with a five-year survival of less than 6.5 percent in patients aged 65 and older [1].
The epidemiology of primary brain tumors is extremely complex and includes lesions with both benign and malignant histologies. Between 1985 and 1992, over 60,000 patients diagnosed with primary brain tumors were reported to the National Cancer Data Base (NCDB) [2], and in this group the most frequent tumors were glioblastoma multiforme (GBM) and astrocytoma. The World Health Organization (WHO) has established a four-level classification system (Grade I to IV) with Grade I being most benign, and Grade IV most malignant. The most malignant tumors - astrocytomas and GBM (Grade III to IV) - had overall 30 percent and two percent five-year survival in the NCDB series [2].</description><identifier>ISSN: 0927-3042</identifier><identifier>ISBN: 0387755861</identifier><identifier>ISBN: 9780387755861</identifier><identifier>EISBN: 9780387755878</identifier><identifier>EISBN: 038775587X</identifier><identifier>DOI: 10.1007/978-0-387-75587-8_3</identifier><identifier>PMID: 18619214</identifier><language>eng</language><publisher>Boston, MA: Springer US</publisher><subject>Biopsy ; Brain - pathology ; Brain Neoplasms - diagnosis ; Brain Neoplasms - pathology ; Cell Proliferation ; Diagnostic Imaging - methods ; Dihydroxyphenylalanine - analogs & derivatives ; Dihydroxyphenylalanine - pharmacology ; Fluorodeoxyglucose F18 - pharmacology ; Humans ; Lipids - chemistry ; Medical Oncology - methods ; Methionine - pharmacology ; Positron-Emission Tomography - methods ; Radiopharmaceuticals - pharmacology ; Tyrosine - analogs & derivatives ; Tyrosine - pharmacology</subject><ispartof>Cancer Treatment and Research, 2008, Vol.143, p.67-92</ispartof><rights>Springer Science+Business Media, LLC 2008</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c2473-58c3fa084fc22435ff55246332f5d65f089757d0a6023e1670a4e22f66fa95393</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/978-0-387-75587-8_3$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/978-0-387-75587-8_3$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,779,780,784,793,27924,27925,38255,41442,42511</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/18619214$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><contributor>Blake, Michael A.</contributor><contributor>Kalra, Mannudeep K.</contributor><creatorcontrib>Fischman, Alan J.</creatorcontrib><title>PET Imaging of Brain Tumors</title><title>Cancer Treatment and Research</title><addtitle>Cancer Treat Res</addtitle><description>The incidence of primary brain tumors is ~ 11:100,000 of the population. In the year 2006, ~ 18,820 new cases of brain and other nervous system tumors were diagnosed in the United States [1] and these tumors were the cause of death in ~ 12,820 patients. Despite advances in diagnosis and therapy, the prognosis for patients with primary brain tumors remains very poor; age-adjusted five-year survival is 30.8 percent. Primary brain tumor is the most prevalent solid tumor in children, and patients 19 years old or younger have a five-year survival of 65 percent. Patients aged 44 or younger have a five-year survival of 58.7 percent. In the elderly, prognosis is extremely poor with a five-year survival of less than 6.5 percent in patients aged 65 and older [1].
The epidemiology of primary brain tumors is extremely complex and includes lesions with both benign and malignant histologies. Between 1985 and 1992, over 60,000 patients diagnosed with primary brain tumors were reported to the National Cancer Data Base (NCDB) [2], and in this group the most frequent tumors were glioblastoma multiforme (GBM) and astrocytoma. The World Health Organization (WHO) has established a four-level classification system (Grade I to IV) with Grade I being most benign, and Grade IV most malignant. The most malignant tumors - astrocytomas and GBM (Grade III to IV) - had overall 30 percent and two percent five-year survival in the NCDB series [2].</description><subject>Biopsy</subject><subject>Brain - pathology</subject><subject>Brain Neoplasms - diagnosis</subject><subject>Brain Neoplasms - pathology</subject><subject>Cell Proliferation</subject><subject>Diagnostic Imaging - methods</subject><subject>Dihydroxyphenylalanine - analogs & derivatives</subject><subject>Dihydroxyphenylalanine - pharmacology</subject><subject>Fluorodeoxyglucose F18 - pharmacology</subject><subject>Humans</subject><subject>Lipids - chemistry</subject><subject>Medical Oncology - methods</subject><subject>Methionine - pharmacology</subject><subject>Positron-Emission Tomography - methods</subject><subject>Radiopharmaceuticals - pharmacology</subject><subject>Tyrosine - analogs & derivatives</subject><subject>Tyrosine - pharmacology</subject><issn>0927-3042</issn><isbn>0387755861</isbn><isbn>9780387755861</isbn><isbn>9780387755878</isbn><isbn>038775587X</isbn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2008</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNo1kE1PwzAMhoMAwTb2CyahnrgFHOf7CNOASZPgMM5R1iVTYW1HQw_8e8I-Lrb8-pElP4RMGNwzAP1gtaFAudFUS5mrcfyMjHMKOdtH5pwMT4NiF2QAFjXlIPCaDFP6BJAaNb8i1yzvLTIxIJP32bKY135TNZuijcVT56umWPZ126Ubchn9NoXxsY_Ix_NsOX2li7eX-fRxQUsUmlNpSh49GBFLRMFljFKiUJxjlGslIxirpV6DV4A8MKXBi4AYlYreSm75iNwd7u669rsP6cfVVSrDduub0PbJIUOBFk0Gb49gv6rD2u26qvbdrzu9kwF2AFJeNZvQuVXbfiXHwP07dNmWA5cVub0wlx3yP4cHWvo</recordid><startdate>2008</startdate><enddate>2008</enddate><creator>Fischman, Alan J.</creator><general>Springer US</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>7QO</scope><scope>7TK</scope><scope>8FD</scope><scope>FR3</scope><scope>P64</scope></search><sort><creationdate>2008</creationdate><title>PET Imaging of Brain Tumors</title><author>Fischman, Alan J.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c2473-58c3fa084fc22435ff55246332f5d65f089757d0a6023e1670a4e22f66fa95393</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2008</creationdate><topic>Biopsy</topic><topic>Brain - pathology</topic><topic>Brain Neoplasms - diagnosis</topic><topic>Brain Neoplasms - pathology</topic><topic>Cell Proliferation</topic><topic>Diagnostic Imaging - methods</topic><topic>Dihydroxyphenylalanine - analogs & derivatives</topic><topic>Dihydroxyphenylalanine - pharmacology</topic><topic>Fluorodeoxyglucose F18 - pharmacology</topic><topic>Humans</topic><topic>Lipids - chemistry</topic><topic>Medical Oncology - methods</topic><topic>Methionine - pharmacology</topic><topic>Positron-Emission Tomography - methods</topic><topic>Radiopharmaceuticals - pharmacology</topic><topic>Tyrosine - analogs & derivatives</topic><topic>Tyrosine - pharmacology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Fischman, Alan J.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>Biotechnology Research Abstracts</collection><collection>Neurosciences Abstracts</collection><collection>Technology Research Database</collection><collection>Engineering Research Database</collection><collection>Biotechnology and BioEngineering Abstracts</collection><jtitle>Cancer Treatment and Research</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Fischman, Alan J.</au><au>Blake, Michael A.</au><au>Kalra, Mannudeep K.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>PET Imaging of Brain Tumors</atitle><jtitle>Cancer Treatment and Research</jtitle><addtitle>Cancer Treat Res</addtitle><date>2008</date><risdate>2008</risdate><volume>143</volume><spage>67</spage><epage>92</epage><pages>67-92</pages><issn>0927-3042</issn><isbn>0387755861</isbn><isbn>9780387755861</isbn><eisbn>9780387755878</eisbn><eisbn>038775587X</eisbn><abstract>The incidence of primary brain tumors is ~ 11:100,000 of the population. In the year 2006, ~ 18,820 new cases of brain and other nervous system tumors were diagnosed in the United States [1] and these tumors were the cause of death in ~ 12,820 patients. Despite advances in diagnosis and therapy, the prognosis for patients with primary brain tumors remains very poor; age-adjusted five-year survival is 30.8 percent. Primary brain tumor is the most prevalent solid tumor in children, and patients 19 years old or younger have a five-year survival of 65 percent. Patients aged 44 or younger have a five-year survival of 58.7 percent. In the elderly, prognosis is extremely poor with a five-year survival of less than 6.5 percent in patients aged 65 and older [1].
The epidemiology of primary brain tumors is extremely complex and includes lesions with both benign and malignant histologies. Between 1985 and 1992, over 60,000 patients diagnosed with primary brain tumors were reported to the National Cancer Data Base (NCDB) [2], and in this group the most frequent tumors were glioblastoma multiforme (GBM) and astrocytoma. The World Health Organization (WHO) has established a four-level classification system (Grade I to IV) with Grade I being most benign, and Grade IV most malignant. The most malignant tumors - astrocytomas and GBM (Grade III to IV) - had overall 30 percent and two percent five-year survival in the NCDB series [2].</abstract><cop>Boston, MA</cop><pub>Springer US</pub><pmid>18619214</pmid><doi>10.1007/978-0-387-75587-8_3</doi><tpages>26</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0927-3042 |
ispartof | Cancer Treatment and Research, 2008, Vol.143, p.67-92 |
issn | 0927-3042 |
language | eng |
recordid | cdi_proquest_miscellaneous_21242928 |
source | MEDLINE; Springer Books |
subjects | Biopsy Brain - pathology Brain Neoplasms - diagnosis Brain Neoplasms - pathology Cell Proliferation Diagnostic Imaging - methods Dihydroxyphenylalanine - analogs & derivatives Dihydroxyphenylalanine - pharmacology Fluorodeoxyglucose F18 - pharmacology Humans Lipids - chemistry Medical Oncology - methods Methionine - pharmacology Positron-Emission Tomography - methods Radiopharmaceuticals - pharmacology Tyrosine - analogs & derivatives Tyrosine - pharmacology |
title | PET Imaging of Brain Tumors |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-01T05%3A46%3A07IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=PET%20Imaging%20of%20Brain%20Tumors&rft.jtitle=Cancer%20Treatment%20and%20Research&rft.au=Fischman,%20Alan%20J.&rft.date=2008&rft.volume=143&rft.spage=67&rft.epage=92&rft.pages=67-92&rft.issn=0927-3042&rft.isbn=0387755861&rft.isbn_list=9780387755861&rft_id=info:doi/10.1007/978-0-387-75587-8_3&rft_dat=%3Cproquest_pubme%3E21242928%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&rft.eisbn=9780387755878&rft.eisbn_list=038775587X&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=21242928&rft_id=info:pmid/18619214&rfr_iscdi=true |